View Financial HealthPrecipio 배당 및 자사주 매입배당 기준 점검 0/6Precipio 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-3.3%자사주 매입 수익률총 주주 수익률-3.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesRecent Insider Transactions Derivative • May 20Independent Chairman of the Board notifies of intention to sell stockRichard Sandberg intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$24.85, it would amount to US$100k. Since June 2025, Richard has owned 75.35k shares directly. Company insiders have collectively sold US$28k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • May 17First quarter 2026 earnings released: US$0.81 loss per share (vs US$0.59 loss in 1Q 2025)First quarter 2026 results: US$0.81 loss per share (further deteriorated from US$0.59 loss in 1Q 2025). Revenue: US$6.71m (up 36% from 1Q 2025). Net loss: US$1.44m (loss widened 63% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.공시 • Apr 29Precipio, Inc., Annual General Meeting, Jun 15, 2026Precipio, Inc., Annual General Meeting, Jun 15, 2026.Reported Earnings • Mar 31Full year 2025 earnings released: US$0.23 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.23 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$24.0m (up 30% from FY 2024). Net loss: US$363.0k (loss narrowed 92% from FY 2024). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.공시 • Mar 11Precipio Inc Announces Bloodhound BCR::ABL1 Assay For Chronic Myeloid LeukemiaPrecipio, Inc. has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). The study analyzed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML, and underscores the key advantage of a single assay that delivers multiple, medically relevant data points simultaneously. The assay can be run in physician office laboratories, regional laboratories and hospitals. The study demonstrates that 25% of patients have multiple forms of BCR::ABL1 breakpoints that are missed because looking for all four requires laboratories to run four different assays (isoforms p190, p210, p230 and p203). No other test delivers all results from the same platform at the same time. Quantitative results for BCR::ABL breakpoints are crucial for the management of CML, providing clinicians a precise, standardized measurement of the disease burden, thereby enabling them to monitor the impact of treatment and detect early relapse. Current assays on the market provide quantitative results only for one breakpoint, p210 (also called “Major transcript”), using an established International Standard (IS) scale. The absence of quantified results for all four breakpoints hinders clinicians' ability to adequately monitor patients if other isoforms other than p210 indicate recurrence. Precipio’s Bloodhound BCR::ABL assay can detect changes as low as 1 in 100,000 cells (0.001%), thereby making it a powerful tool for monitoring measurable residual disease (MRD). At these low levels, early trends in these isoforms can provide months of advanced warning time that other, less sensitive or qualitative assays may not detect. The diagnosis and therapeutic decision-making in CML depend on the detection and quantification of BCR::ABL1. Until now, no clinical assay existed that could simultaneously test multiple BCR::ABL1 isoforms and provide quantified results, therefore requiring laboratories to run separate tests for each isoform. To address this challenge, Precipio developed the BloodHound assay, enabling laboratories to provide proper, comprehensive testing for CML patients. The assay runs all 4 breakpoints on a single, pre-plated plate run (with all controls provided) on a RT-PCR machine. Precipio’s custom-developed analysis software provides fully quantified automated results including molecular response criteria. The BCR::ABL1 test provides important diagnostic criteria for patients with AML, ALL and MPN. The new Precipio test simplifies workflow into one assay, is standardizable across laboratories, is quantitative and, importantly, provides target genetic markers to enable monitoring disease for years over the treatment course.공시 • Dec 05Precipio, Inc. to Showcase Its BCR::ABL1 Panel At 2025 Ash (American Society of Hematology) MeetingPrecipio, Inc. will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows.New Risk • Nov 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Significant insider selling over the past 3 months (US$123k sold). Market cap is less than US$100m (US$42.9m market cap).분석 기사 • Nov 19Precipio, Inc. (NASDAQ:PRPO) Stock Rockets 28% But Many Are Still Ignoring The CompanyPrecipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 28% gain in the last month alone. The...Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.048 loss per share (vs US$0.42 loss in 3Q 2024)Third quarter 2025 results: US$0.048 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$6.77m (up 30% from 3Q 2024). Net loss: US$79.0k (loss narrowed 87% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$123k sold). Market cap is less than US$100m (US$28.8m market cap).분석 기사 • Sep 08Precipio, Inc.'s (NASDAQ:PRPO) Shares Leap 28% Yet They're Still Not Telling The Full StoryPrecipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 28% gain in the last month alone. The...공시 • Sep 04Precipio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $1.061478 million.Precipio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $1.061478 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Aug 14Second quarter 2025 earnings released: EPS: US$0.049 (vs US$0.83 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.049 (up from US$0.83 loss in 2Q 2024). Revenue: US$5.65m (up 27% from 2Q 2024). Net income: US$74.0k (up US$1.29m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 07Precipio: Cash Flow Positivity May Remove Going Concern LanguageSummary Precipio is a microcap cancer diagnostics firm with proprietary assays and culture media, targeting a growing niche in hematologic oncology diagnostics. Recent cost controls, margin expansion, and MolDx Medicare approval position Precipio to achieve positive cash flow and remove 'going concern' audit language by early 2026. The company’s differentiated products, strong distribution partnerships, and disciplined management support multi-year revenue growth and margin expansion. Precipio trades at a deep discount to peers; successful execution could drive 2–4x upside as valuation re-rates with improved financials and institutional interest. Read the full article on Seeking Alpha분석 기사 • Jul 12Further Upside For Precipio, Inc. (NASDAQ:PRPO) Shares Could Introduce Price Risks After 41% BouncePrecipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 41% gain in the last month alone. The...Recent Insider Transactions • May 25Independent Chairman of the Board recently bought US$74k worth of stockOn the 21st of May, Richard Sandberg bought around 8k shares on-market at roughly US$9.27 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of US$125k worth in shares.Reported Earnings • May 15First quarter 2025 earnings released: US$0.59 loss per share (vs US$1.46 loss in 1Q 2024)First quarter 2025 results: US$0.59 loss per share (improved from US$1.46 loss in 1Q 2024). Revenue: US$4.93m (up 44% from 1Q 2024). Net loss: US$884.0k (loss narrowed 57% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • May 01Precipio, Inc., Annual General Meeting, Jun 17, 2025Precipio, Inc., Annual General Meeting, Jun 17, 2025.New Risk • Apr 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (US$8.20m market cap).Reported Earnings • Mar 28Full year 2024 earnings released: US$2.93 loss per share (vs US$4.51 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$4.51 loss in FY 2023). Revenue: US$18.5m (up 22% from FY 2023). Net loss: US$4.29m (loss narrowed 27% from FY 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.New Risk • Feb 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$11.9m market cap).분석 기사 • Feb 20Investors Still Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues Despite 28% Price JumpDespite an already strong run, Precipio, Inc. ( NASDAQ:PRPO ) shares have been powering on, with a gain of 28% in the...분석 기사 • Dec 20Investors Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.5x Precipio, Inc. ( NASDAQ:PRPO ) is a stock worth...Recent Insider Transactions • Dec 16Independent Chairman of the Board recently bought US$87k worth of stockOn the 13th of December, Richard Sandberg bought around 15k shares on-market at roughly US$5.80 per share. This transaction increased Richard's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of US$13k worth in shares.Recent Insider Transactions Derivative • Dec 12Independent Chairman of the Board notifies of intention to sell stockRichard Sandberg intends to sell 14k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$5.90, it would amount to US$83k. Since June 2024, Richard's direct individual holding has decreased from 16.03k shares to 42.00. There have been no trades via on-market transactions or options from company insiders in the last 12 months.Reported Earnings • Nov 08Third quarter 2024 earnings released: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)Third quarter 2024 results: US$0.42 loss per share (improved from US$1.04 loss in 3Q 2023). Revenue: US$5.21m (up 15% from 3Q 2023). Net loss: US$626.0k (loss narrowed 57% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.공시 • Oct 09Precipio Expands Bloodhound MPN Panel by Adding CALR Mutation SubtypingPrecipio, Inc. announced the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024--August 8, 2024). This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN. The inclusion of CALR mutation subtyping is a direct response to the evolving landscape of MPN patient care where understanding the specific type of CALR mutation can influence treatment strategies and outcomes. The CALR gene mutation is prevalent in various myeloproliferative neoplasms and plays a critical role in disease prognosis and therapeutic decision-making. The distinction between CALR type1 and type 2 can indicate the severity of disease progression (prognosis) and inform the physician on the specific treatment needed to suit the patient's situation. Furthermore, for patients with dual mutations (e.g. JAK2 & CALR), the identification of the subtype CALR mutation present can impact the selection of targeted therapies. With the recent updates from the NCCN, healthcare providers are looking for more detailed information regarding CALR mutations, allowing them to better manage MPN patient care. Precipio's new Bloodhound MPN assay provides them with exactly what they need to help specify an MPN subtype and to determine which CALR-positive patients may respond to CALR-targeted therapies.분석 기사 • Aug 21Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price BoostPrecipio, Inc. ( NASDAQ:PRPO ) shareholders would be excited to see that the share price has had a great month, posting...Reported Earnings • Aug 15Second quarter 2024 earnings released: US$0.83 loss per share (vs US$1.88 loss in 2Q 2023)Second quarter 2024 results: US$0.83 loss per share (improved from US$1.88 loss in 2Q 2023). Revenue: US$4.44m (up 26% from 2Q 2023). Net loss: US$1.22m (loss narrowed 47% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.New Risk • Jul 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.8m free cash flow). Market cap is less than US$10m (US$6.52m market cap). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (6.6% increase in shares outstanding).분석 기사 • Jun 07Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay PacketKey Insights Precipio will host its Annual General Meeting on 13th of June Total pay for CEO Ilan Danieli includes...Reported Earnings • May 16First quarter 2024 earnings released: US$1.46 loss per share (vs US$2.61 loss in 1Q 2023)First quarter 2024 results: US$1.46 loss per share (improved from US$2.61 loss in 1Q 2023). Revenue: US$3.43m (up 22% from 1Q 2023). Net loss: US$2.08m (loss narrowed 31% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.New Risk • May 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Market cap is less than US$10m (US$8.35m market cap). Minor Risk Shareholders have been diluted in the past year (25% increase in shares outstanding).공시 • May 01Precipio, Inc., Annual General Meeting, Jun 13, 2024Precipio, Inc., Annual General Meeting, Jun 13, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect Kathleen D. LaPorte and Ron A. Andrews as ClassIII directors for terms to expire in 2027; to hold an advisory (non-binding) vote to approve named executive compensation; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the year ending December31, 2024; to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.Reported Earnings • Mar 31Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022)Full year 2023 results: US$4.51 loss per share (improved from US$10.73 loss in FY 2022). Revenue: US$15.2m (up 62% from FY 2022). Net loss: US$5.85m (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.분석 기사 • Mar 29Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)With a median price-to-sales (or "P/S") ratio of close to 1.1x in the Healthcare industry in the United States, you...공시 • Jan 02Precipio, Inc. Announces Board ChangesPrecipio, Inc. welcomed Christina Valauri to its board of directors effective January 1, 2024. Ms. Valauri is joining Precipio’s board to support management’s understanding of and interaction with the capital markets, as the company look towards 2024 to be an important period for the company from both a business growth, and financial perspective. Ms. Valauri brings a 30-year proven track record as a senior healthcare analyst and has held leadership roles that include US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald, and senior equity research management roles at firms including ING, Credit Lyonnais (acquired by Credit Agricole), and Natixis. She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC. Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. Ms. Valauri currently serves as an Entrepreneur In Residence at Weill Cornell Medicine BioVenture eLab where she applies her skills and experience in life sciences and business to support the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of researchers, and clinicians. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University. After serving on Precipio’s board of directors for 6 years, Douglas Fisher, MD is stepping off the board to maintain a board of 7 directors and will remain as an observer moving forward.Reported Earnings • Nov 16Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$1.04 loss per share (improved from US$2.79 loss in 3Q 2022). Revenue: US$4.52m (up 104% from 3Q 2022). Net loss: US$1.46m (loss narrowed 54% from 3Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 26%. Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.공시 • Sep 22Precipio Takes Final Step Towards Regaining Nasdaq CompliancePrecipio, Inc. announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00. A reverse split essentially means a decrease in the number of shares and a proportional increase in the value of the share price. Therefore, the reverse split in itself has no impact on the aggregate value of stock held by you as a shareholder. The primary goal of the reverse stock split is to increase the per share market price of the company’s common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. As you may know, many individual investors, and some institutional investors, are prohibited from trading shares of companies below $2, and some are prohibited from trading shares below $5. The post-reverse stock split share price should enable the company to broaden its potential pool of investors to include both individual and institutional investors who face such restrictions. This is expected to increase demand for the stock. “I understand the disappointment many of our shareholders feel, and the negative sentiment attached to the reverse stock split. I urge you to look at our company performance as measured by revenues, margins and cash, and you will see a good story developing”, said Ilan Danieli, Chief Executive Officer.분석 기사 • Aug 29Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An OpportunityIt's not a stretch to say that Precipio, Inc.'s ( NASDAQ:PRPO ) price-to-sales (or "P/S") ratio of 0.9x right now seems...Major Estimate Revision • Aug 20Consensus revenue estimates increase by 11%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$13.7m to US$15.2m. Forecast losses expected to reduce from -US$0.34 to -US$0.33 per share. Healthcare industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$2.00 unchanged from last update. Share price was steady at US$0.36 over the past week.New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.7m free cash flow). Market cap is less than US$10m (US$9.92m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$3.6m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.094 loss per share (in line with 2Q 2022). Revenue: US$3.53m (up 50% from 2Q 2022). Net loss: US$2.29m (loss widened 6.9% from 2Q 2022). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.New Risk • Jun 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.96m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.96m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.2m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.7m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).공시 • May 24Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyPrecipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190). While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician. Changes in isoform expression may happen over time during the course of treatment. The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.Reported Earnings • May 14First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2023 results: US$0.13 loss per share (improved from US$0.20 loss in 1Q 2022). Revenue: US$2.82m (up 15% from 1Q 2022). Net loss: US$3.03m (loss narrowed 34% from 1Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 02Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021)Full year 2022 results: US$0.54 loss per share (further deteriorated from US$0.40 loss in FY 2021). Revenue: US$9.41m (up 6.4% from FY 2021). Net loss: US$12.2m (loss widened 43% from FY 2021). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Price Target Changed • Nov 16Price target decreased to US$4.00Down from US$7.00, the current price target is provided by 1 analyst. New target price is 400% above last closing price of US$0.80. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.37 next year compared to a net loss per share of US$0.40 last year.Reported Earnings • Nov 12Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.14 loss per share (further deteriorated from US$0.082 loss in 3Q 2021). Revenue: US$2.22m (down 1.4% from 3Q 2021). Net loss: US$3.18m (loss widened 71% from 3Q 2021). Revenue missed analyst estimates by 56%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021)Second quarter 2022 results: US$0.094 loss per share (up from US$0.14 loss in 2Q 2021). Revenue: US$2.36m (flat on 2Q 2021). Net loss: US$2.14m (loss narrowed 29% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 04Forecast to breakeven in 2023The analyst covering Precipio expects the company to break even for the first time. New forecast suggests the company will make a profit of US$123.0k in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Seeking Alpha • Jul 20Precipio to distribute HemeScreen through Fisher Healthcare channelPrecipio (NASDAQ:PRPO) has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers. The Fisher Healthcare channel will enable Precipio to expand access to laboratories across the U.S. for Precipio’s HemeScreen suite of products. This partnership is a logical expansion of Precipio’s distribution strategy, the leveraging of industry leading sales channels rather than building its own sales force. “The HemeScreen technology excels in these areas and will support the Fisher Healthcare channel in its commitment to serve its customers.” said Keith Meadors, Precipio’s Senior VP of Products.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.20 loss per share (down from US$0.081 loss in 1Q 2021). Revenue: US$2.45m (up 34% from 1Q 2021). Net loss: US$4.59m (loss widened 216% from 1Q 2021). Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 300%. Over the next year, revenue is forecast to grow 162%, compared to a 8.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$7.00, the current price target is provided by 1 analyst. New target price is 281% above last closing price of US$1.05. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$0.21 next year compared to a net loss per share of US$0.40 last year.Reported Earnings • Apr 01Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.40 loss per share (up from US$0.85 loss in FY 2020). Revenue: US$8.85m (up 45% from FY 2020). Net loss: US$8.53m (loss narrowed 39% from FY 2020). Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) exceeded analyst estimates by 8.1%. Over the next year, revenue is forecast to grow 136%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$2.25m (up 38% from 3Q 2020). Net loss: US$1.86m (loss narrowed 44% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 14Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$2.34m (up 79% from 2Q 2020). Net loss: US$3.01m (loss widened 34% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.분석 기사 • Jun 12We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO CompensationIn the past three years, the share price of Precipio, Inc. ( NASDAQ:PRPO ) has struggled to grow and now shareholders...Reported Earnings • May 16First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$1.82m (up 50% from 1Q 2020). Net loss: US$1.45m (loss narrowed 78% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Price Target Changed • May 03Price target increased to US$7.00Up from US$5.15, the current price target is provided by 1 analyst. New target price is 285% above last closing price of US$1.82. Stock is up 151% over the past year.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PRPO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PRPO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Precipio 배당 수익률 vs 시장PRPO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PRPO)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Healthcare)2.0%분석가 예측 (PRPO) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PRPO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PRPO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PRPO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PRPO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/05 00:43종가2026/06/05 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Precipio, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Benjamin HaynorAlliance Global PartnersJason McCarthyMaxim Group
Recent Insider Transactions Derivative • May 20Independent Chairman of the Board notifies of intention to sell stockRichard Sandberg intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of May. If the sale is conducted around the recent share price of US$24.85, it would amount to US$100k. Since June 2025, Richard has owned 75.35k shares directly. Company insiders have collectively sold US$28k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • May 17First quarter 2026 earnings released: US$0.81 loss per share (vs US$0.59 loss in 1Q 2025)First quarter 2026 results: US$0.81 loss per share (further deteriorated from US$0.59 loss in 1Q 2025). Revenue: US$6.71m (up 36% from 1Q 2025). Net loss: US$1.44m (loss widened 63% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
공시 • Apr 29Precipio, Inc., Annual General Meeting, Jun 15, 2026Precipio, Inc., Annual General Meeting, Jun 15, 2026.
Reported Earnings • Mar 31Full year 2025 earnings released: US$0.23 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.23 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$24.0m (up 30% from FY 2024). Net loss: US$363.0k (loss narrowed 92% from FY 2024). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
공시 • Mar 11Precipio Inc Announces Bloodhound BCR::ABL1 Assay For Chronic Myeloid LeukemiaPrecipio, Inc. has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). The study analyzed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML, and underscores the key advantage of a single assay that delivers multiple, medically relevant data points simultaneously. The assay can be run in physician office laboratories, regional laboratories and hospitals. The study demonstrates that 25% of patients have multiple forms of BCR::ABL1 breakpoints that are missed because looking for all four requires laboratories to run four different assays (isoforms p190, p210, p230 and p203). No other test delivers all results from the same platform at the same time. Quantitative results for BCR::ABL breakpoints are crucial for the management of CML, providing clinicians a precise, standardized measurement of the disease burden, thereby enabling them to monitor the impact of treatment and detect early relapse. Current assays on the market provide quantitative results only for one breakpoint, p210 (also called “Major transcript”), using an established International Standard (IS) scale. The absence of quantified results for all four breakpoints hinders clinicians' ability to adequately monitor patients if other isoforms other than p210 indicate recurrence. Precipio’s Bloodhound BCR::ABL assay can detect changes as low as 1 in 100,000 cells (0.001%), thereby making it a powerful tool for monitoring measurable residual disease (MRD). At these low levels, early trends in these isoforms can provide months of advanced warning time that other, less sensitive or qualitative assays may not detect. The diagnosis and therapeutic decision-making in CML depend on the detection and quantification of BCR::ABL1. Until now, no clinical assay existed that could simultaneously test multiple BCR::ABL1 isoforms and provide quantified results, therefore requiring laboratories to run separate tests for each isoform. To address this challenge, Precipio developed the BloodHound assay, enabling laboratories to provide proper, comprehensive testing for CML patients. The assay runs all 4 breakpoints on a single, pre-plated plate run (with all controls provided) on a RT-PCR machine. Precipio’s custom-developed analysis software provides fully quantified automated results including molecular response criteria. The BCR::ABL1 test provides important diagnostic criteria for patients with AML, ALL and MPN. The new Precipio test simplifies workflow into one assay, is standardizable across laboratories, is quantitative and, importantly, provides target genetic markers to enable monitoring disease for years over the treatment course.
공시 • Dec 05Precipio, Inc. to Showcase Its BCR::ABL1 Panel At 2025 Ash (American Society of Hematology) MeetingPrecipio, Inc. will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows.
New Risk • Nov 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Significant insider selling over the past 3 months (US$123k sold). Market cap is less than US$100m (US$42.9m market cap).
분석 기사 • Nov 19Precipio, Inc. (NASDAQ:PRPO) Stock Rockets 28% But Many Are Still Ignoring The CompanyPrecipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 28% gain in the last month alone. The...
Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.048 loss per share (vs US$0.42 loss in 3Q 2024)Third quarter 2025 results: US$0.048 loss per share (improved from US$0.42 loss in 3Q 2024). Revenue: US$6.77m (up 30% from 3Q 2024). Net loss: US$79.0k (loss narrowed 87% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$123k sold). Market cap is less than US$100m (US$28.8m market cap).
분석 기사 • Sep 08Precipio, Inc.'s (NASDAQ:PRPO) Shares Leap 28% Yet They're Still Not Telling The Full StoryPrecipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 28% gain in the last month alone. The...
공시 • Sep 04Precipio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $1.061478 million.Precipio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $1.061478 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Aug 14Second quarter 2025 earnings released: EPS: US$0.049 (vs US$0.83 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.049 (up from US$0.83 loss in 2Q 2024). Revenue: US$5.65m (up 27% from 2Q 2024). Net income: US$74.0k (up US$1.29m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 07Precipio: Cash Flow Positivity May Remove Going Concern LanguageSummary Precipio is a microcap cancer diagnostics firm with proprietary assays and culture media, targeting a growing niche in hematologic oncology diagnostics. Recent cost controls, margin expansion, and MolDx Medicare approval position Precipio to achieve positive cash flow and remove 'going concern' audit language by early 2026. The company’s differentiated products, strong distribution partnerships, and disciplined management support multi-year revenue growth and margin expansion. Precipio trades at a deep discount to peers; successful execution could drive 2–4x upside as valuation re-rates with improved financials and institutional interest. Read the full article on Seeking Alpha
분석 기사 • Jul 12Further Upside For Precipio, Inc. (NASDAQ:PRPO) Shares Could Introduce Price Risks After 41% BouncePrecipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 41% gain in the last month alone. The...
Recent Insider Transactions • May 25Independent Chairman of the Board recently bought US$74k worth of stockOn the 21st of May, Richard Sandberg bought around 8k shares on-market at roughly US$9.27 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of US$125k worth in shares.
Reported Earnings • May 15First quarter 2025 earnings released: US$0.59 loss per share (vs US$1.46 loss in 1Q 2024)First quarter 2025 results: US$0.59 loss per share (improved from US$1.46 loss in 1Q 2024). Revenue: US$4.93m (up 44% from 1Q 2024). Net loss: US$884.0k (loss narrowed 57% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • May 01Precipio, Inc., Annual General Meeting, Jun 17, 2025Precipio, Inc., Annual General Meeting, Jun 17, 2025.
New Risk • Apr 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (US$8.20m market cap).
Reported Earnings • Mar 28Full year 2024 earnings released: US$2.93 loss per share (vs US$4.51 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$4.51 loss in FY 2023). Revenue: US$18.5m (up 22% from FY 2023). Net loss: US$4.29m (loss narrowed 27% from FY 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
New Risk • Feb 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$11.9m market cap).
분석 기사 • Feb 20Investors Still Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues Despite 28% Price JumpDespite an already strong run, Precipio, Inc. ( NASDAQ:PRPO ) shares have been powering on, with a gain of 28% in the...
분석 기사 • Dec 20Investors Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.5x Precipio, Inc. ( NASDAQ:PRPO ) is a stock worth...
Recent Insider Transactions • Dec 16Independent Chairman of the Board recently bought US$87k worth of stockOn the 13th of December, Richard Sandberg bought around 15k shares on-market at roughly US$5.80 per share. This transaction increased Richard's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of US$13k worth in shares.
Recent Insider Transactions Derivative • Dec 12Independent Chairman of the Board notifies of intention to sell stockRichard Sandberg intends to sell 14k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$5.90, it would amount to US$83k. Since June 2024, Richard's direct individual holding has decreased from 16.03k shares to 42.00. There have been no trades via on-market transactions or options from company insiders in the last 12 months.
Reported Earnings • Nov 08Third quarter 2024 earnings released: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)Third quarter 2024 results: US$0.42 loss per share (improved from US$1.04 loss in 3Q 2023). Revenue: US$5.21m (up 15% from 3Q 2023). Net loss: US$626.0k (loss narrowed 57% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
공시 • Oct 09Precipio Expands Bloodhound MPN Panel by Adding CALR Mutation SubtypingPrecipio, Inc. announced the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024--August 8, 2024). This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN. The inclusion of CALR mutation subtyping is a direct response to the evolving landscape of MPN patient care where understanding the specific type of CALR mutation can influence treatment strategies and outcomes. The CALR gene mutation is prevalent in various myeloproliferative neoplasms and plays a critical role in disease prognosis and therapeutic decision-making. The distinction between CALR type1 and type 2 can indicate the severity of disease progression (prognosis) and inform the physician on the specific treatment needed to suit the patient's situation. Furthermore, for patients with dual mutations (e.g. JAK2 & CALR), the identification of the subtype CALR mutation present can impact the selection of targeted therapies. With the recent updates from the NCCN, healthcare providers are looking for more detailed information regarding CALR mutations, allowing them to better manage MPN patient care. Precipio's new Bloodhound MPN assay provides them with exactly what they need to help specify an MPN subtype and to determine which CALR-positive patients may respond to CALR-targeted therapies.
분석 기사 • Aug 21Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price BoostPrecipio, Inc. ( NASDAQ:PRPO ) shareholders would be excited to see that the share price has had a great month, posting...
Reported Earnings • Aug 15Second quarter 2024 earnings released: US$0.83 loss per share (vs US$1.88 loss in 2Q 2023)Second quarter 2024 results: US$0.83 loss per share (improved from US$1.88 loss in 2Q 2023). Revenue: US$4.44m (up 26% from 2Q 2023). Net loss: US$1.22m (loss narrowed 47% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
New Risk • Jul 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.8m free cash flow). Market cap is less than US$10m (US$6.52m market cap). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (6.6% increase in shares outstanding).
분석 기사 • Jun 07Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay PacketKey Insights Precipio will host its Annual General Meeting on 13th of June Total pay for CEO Ilan Danieli includes...
Reported Earnings • May 16First quarter 2024 earnings released: US$1.46 loss per share (vs US$2.61 loss in 1Q 2023)First quarter 2024 results: US$1.46 loss per share (improved from US$2.61 loss in 1Q 2023). Revenue: US$3.43m (up 22% from 1Q 2023). Net loss: US$2.08m (loss narrowed 31% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
New Risk • May 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Market cap is less than US$10m (US$8.35m market cap). Minor Risk Shareholders have been diluted in the past year (25% increase in shares outstanding).
공시 • May 01Precipio, Inc., Annual General Meeting, Jun 13, 2024Precipio, Inc., Annual General Meeting, Jun 13, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect Kathleen D. LaPorte and Ron A. Andrews as ClassIII directors for terms to expire in 2027; to hold an advisory (non-binding) vote to approve named executive compensation; to ratify the appointment of Marcum LLP as independent registered public accounting firm for the year ending December31, 2024; to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
Reported Earnings • Mar 31Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022)Full year 2023 results: US$4.51 loss per share (improved from US$10.73 loss in FY 2022). Revenue: US$15.2m (up 62% from FY 2022). Net loss: US$5.85m (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 29Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)With a median price-to-sales (or "P/S") ratio of close to 1.1x in the Healthcare industry in the United States, you...
공시 • Jan 02Precipio, Inc. Announces Board ChangesPrecipio, Inc. welcomed Christina Valauri to its board of directors effective January 1, 2024. Ms. Valauri is joining Precipio’s board to support management’s understanding of and interaction with the capital markets, as the company look towards 2024 to be an important period for the company from both a business growth, and financial perspective. Ms. Valauri brings a 30-year proven track record as a senior healthcare analyst and has held leadership roles that include US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald, and senior equity research management roles at firms including ING, Credit Lyonnais (acquired by Credit Agricole), and Natixis. She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC. Her background in equity securities research has provided a deep base of experience in pharmaceutical, biotech, and med-tech companies. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs. Ms. Valauri currently serves as an Entrepreneur In Residence at Weill Cornell Medicine BioVenture eLab where she applies her skills and experience in life sciences and business to support the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of researchers, and clinicians. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University. After serving on Precipio’s board of directors for 6 years, Douglas Fisher, MD is stepping off the board to maintain a board of 7 directors and will remain as an observer moving forward.
Reported Earnings • Nov 16Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$1.04 loss per share (improved from US$2.79 loss in 3Q 2022). Revenue: US$4.52m (up 104% from 3Q 2022). Net loss: US$1.46m (loss narrowed 54% from 3Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 26%. Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
공시 • Sep 22Precipio Takes Final Step Towards Regaining Nasdaq CompliancePrecipio, Inc. announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00. A reverse split essentially means a decrease in the number of shares and a proportional increase in the value of the share price. Therefore, the reverse split in itself has no impact on the aggregate value of stock held by you as a shareholder. The primary goal of the reverse stock split is to increase the per share market price of the company’s common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. As you may know, many individual investors, and some institutional investors, are prohibited from trading shares of companies below $2, and some are prohibited from trading shares below $5. The post-reverse stock split share price should enable the company to broaden its potential pool of investors to include both individual and institutional investors who face such restrictions. This is expected to increase demand for the stock. “I understand the disappointment many of our shareholders feel, and the negative sentiment attached to the reverse stock split. I urge you to look at our company performance as measured by revenues, margins and cash, and you will see a good story developing”, said Ilan Danieli, Chief Executive Officer.
분석 기사 • Aug 29Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An OpportunityIt's not a stretch to say that Precipio, Inc.'s ( NASDAQ:PRPO ) price-to-sales (or "P/S") ratio of 0.9x right now seems...
Major Estimate Revision • Aug 20Consensus revenue estimates increase by 11%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$13.7m to US$15.2m. Forecast losses expected to reduce from -US$0.34 to -US$0.33 per share. Healthcare industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$2.00 unchanged from last update. Share price was steady at US$0.36 over the past week.
New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.7m free cash flow). Market cap is less than US$10m (US$9.92m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$3.6m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.094 loss per share (in line with 2Q 2022). Revenue: US$3.53m (up 50% from 2Q 2022). Net loss: US$2.29m (loss widened 6.9% from 2Q 2022). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
New Risk • Jun 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.96m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.96m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.2m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.7m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).
공시 • May 24Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyPrecipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190). While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician. Changes in isoform expression may happen over time during the course of treatment. The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.
Reported Earnings • May 14First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2023 results: US$0.13 loss per share (improved from US$0.20 loss in 1Q 2022). Revenue: US$2.82m (up 15% from 1Q 2022). Net loss: US$3.03m (loss narrowed 34% from 1Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 02Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021)Full year 2022 results: US$0.54 loss per share (further deteriorated from US$0.40 loss in FY 2021). Revenue: US$9.41m (up 6.4% from FY 2021). Net loss: US$12.2m (loss widened 43% from FY 2021). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Nov 16Price target decreased to US$4.00Down from US$7.00, the current price target is provided by 1 analyst. New target price is 400% above last closing price of US$0.80. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$0.37 next year compared to a net loss per share of US$0.40 last year.
Reported Earnings • Nov 12Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.14 loss per share (further deteriorated from US$0.082 loss in 3Q 2021). Revenue: US$2.22m (down 1.4% from 3Q 2021). Net loss: US$3.18m (loss widened 71% from 3Q 2021). Revenue missed analyst estimates by 56%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021)Second quarter 2022 results: US$0.094 loss per share (up from US$0.14 loss in 2Q 2021). Revenue: US$2.36m (flat on 2Q 2021). Net loss: US$2.14m (loss narrowed 29% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 04Forecast to breakeven in 2023The analyst covering Precipio expects the company to break even for the first time. New forecast suggests the company will make a profit of US$123.0k in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Seeking Alpha • Jul 20Precipio to distribute HemeScreen through Fisher Healthcare channelPrecipio (NASDAQ:PRPO) has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers. The Fisher Healthcare channel will enable Precipio to expand access to laboratories across the U.S. for Precipio’s HemeScreen suite of products. This partnership is a logical expansion of Precipio’s distribution strategy, the leveraging of industry leading sales channels rather than building its own sales force. “The HemeScreen technology excels in these areas and will support the Fisher Healthcare channel in its commitment to serve its customers.” said Keith Meadors, Precipio’s Senior VP of Products.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.20 loss per share (down from US$0.081 loss in 1Q 2021). Revenue: US$2.45m (up 34% from 1Q 2021). Net loss: US$4.59m (loss widened 216% from 1Q 2021). Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 300%. Over the next year, revenue is forecast to grow 162%, compared to a 8.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$4.00Down from US$7.00, the current price target is provided by 1 analyst. New target price is 281% above last closing price of US$1.05. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$0.21 next year compared to a net loss per share of US$0.40 last year.
Reported Earnings • Apr 01Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.40 loss per share (up from US$0.85 loss in FY 2020). Revenue: US$8.85m (up 45% from FY 2020). Net loss: US$8.53m (loss narrowed 39% from FY 2020). Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) exceeded analyst estimates by 8.1%. Over the next year, revenue is forecast to grow 136%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$2.25m (up 38% from 3Q 2020). Net loss: US$1.86m (loss narrowed 44% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 14Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$2.34m (up 79% from 2Q 2020). Net loss: US$3.01m (loss widened 34% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 12We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO CompensationIn the past three years, the share price of Precipio, Inc. ( NASDAQ:PRPO ) has struggled to grow and now shareholders...
Reported Earnings • May 16First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$1.82m (up 50% from 1Q 2020). Net loss: US$1.45m (loss narrowed 78% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Price Target Changed • May 03Price target increased to US$7.00Up from US$5.15, the current price target is provided by 1 analyst. New target price is 285% above last closing price of US$1.82. Stock is up 151% over the past year.